Online inquiry

IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3310MR)

This product GTTS-WQ3310MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets lukG&lukH gene. The antibody can be applied in Staphylococcal infections research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq WP_000791407.1; WP_000791411.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 59700810; 59700811
UniProt ID A0A390DBJ6; A0A390DBJ6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ3310MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11922MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ13842MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ6725MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ5540MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ7869MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ5879MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIFN
GTTS-WQ5745MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ9187MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN853
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW